Abbott Laboratories Website

Abbott Laboratories

NYSE-ABT

Basic

  • Market Cap

    $184.33B

  • EV

    $192.62B

  • Shares Out

    1,739.63M

  • Revenue

    $40.73B

  • Employees

    114,000

Margins

  • Gross

    55.46%

  • EBITDA

    25.75%

  • Operating

    17.77%

  • Pre-Tax

    15.98%

  • Net

    13.65%

  • FCF

    12.61%

Returns (5Yr Avg)

  • ROA

    7.78%

  • ROTA

    27.94%

  • ROE

    16.23%

  • ROCE

    12.15%

  • ROIC

    11.46%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $124.47

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    $6,651M

  • Net Debt

    $8,054M

  • Debt/Equity

    0.38

  • EBIT/Interest

    11.26

Growth (CAGR)

  • Rev 3Yr

    0.41%

  • Rev 5Yr

    5.65%

  • Rev 10Yr

    7.56%

  • Dil EPS 3Yr

    -3.7%

  • Dil EPS 5Yr

    14.28%

  • Dil EPS 10Yr

    7.47%

  • Rev Fwd 2Yr

    5.67%

  • EBITDA Fwd 2Yr

    6.82%

  • EPS Fwd 2Yr

    7.58%

  • EPS LT Growth Est

    8.45%

Dividends

  • Yield

    —

  • Payout

    67.88%

  • DPS

    $2.16

  • DPS Growth 3Yr

    8.1%

  • DPS Growth 5Yr

    11.74%

  • DPS Growth 10Yr

    10.44%

  • DPS Growth Fwd 2Yr

    7.17%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Total Revenues

31,904

34,608

43,075

43,653

40,109

40,725

Total Revenues % Chg.

4.3%

8.5%

24.5%

1.3%

-8.1%

1.2%

Cost of Goods Sold, Total

13,231

15,003

18,080

19,083

17,919

18,139

Gross Profit

18,673

19,605

24,995

24,570

22,190

22,586

Selling General & Admin Expenses, Total

9,540

9,591

11,006

10,703

10,385

10,795

R&D Expenses

2,440

2,420

2,738

2,741

2,619

2,633

Amortization of Goodwill and Intangible Assets

1,936

2,132

2,047

2,013

1,966

1,920

Other Operating Expenses, Total

13,916

14,143

15,791

15,457

14,970

15,348

Operating Income

4,757

5,462

9,204

9,113

7,220

7,238

Interest Expense, Total

-670

-546

-533

-558

-637

-643

Interest And Investment Income

94

46

43

183

385

385

Net Interest Expenses

-576

-500

-490

-375

-252

-258

Currency Exchange Gains (Loss)

-7

8

-1

-2

-41

-8

Other Non Operating Income (Expenses)

—

-34

13

7

-40

-22

-384

EBT, Excl. Unusual Items

4,140

4,983

8,720

8,696

6,905

6,588

Restructuring Charges

—

—

-509

-234

-144

-164

Merger & Related Restructuring Charges

—

—

—

—

—

—

—

—

—

—

Gain (Loss) On Sale Of Investments

—

—

-115

—

-45

-39

-39

Gain (Loss) On Sale Of Assets

—

—

—

—

—

—

—

—

—

—

Asset Writedown

—

—

—

—

—

—

—

—

-111

-100

-100

Legal Settlements

—

—

—

—

—

—

100

—

—

—

—

Other Unusual Items

—

—

-63

—

—

—

42

224

EBT, Incl. Unusual Items

4,077

4,968

8,211

8,306

6,664

6,509

Income Tax Expense

390

497

1,140

1,373

941

952

Earnings From Continuing Operations

3,687

4,471

7,071

6,933

5,723

5,557

Earnings Of Discontinued Operations

—

24

—

—

—

—

Net Income

3,687

4,495

7,071

6,933

5,723

5,557

Preferred Dividend and Other Adjustments

21

22

29

28

22

22

Net Income to Common Incl Extra Items

3,666

4,473

7,042

6,905

5,701

5,535

Net Income to Common Excl. Extra Items

3,666

4,449

7,042

6,905

5,701

5,535

Total Shares Outstanding

1,762.5

1,771.2

1,764.1

1,737.8

1,734.1

1,751

Weighted Avg. Shares Outstanding

1,768

1,773

1,775

1,753

1,740

1,739.5

Weighted Avg. Shares Outstanding Dil

1,781

1,786

1,789

1,764

1,749

1,748.5

EPS

2.1

2.5

4

3.9

3.3

3.2

EPS Diluted

2.1

2.5

3.9

3.9

3.3

3.2

EBITDA

7,771

8,789

12,742

12,380

10,463

10,485

Effective Tax Rate

9.6%

10%

13.9%

16.5%

14.1%

14.6%